Learn how a 25% Pharma tariff could raise U.S. drug costs by nearly $51 billion annually and impact prices significantly.

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics.

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...

With UPLIZNA receiving a label expansion that opens the door to a previously untapped rare disease market, Amgen is seeing strong returns on its USD 27.8 billion acquisition of Horizon Therapeutics.

With travel warnings and revoked visas, the two superpowers locked in a bruising trade war may make students and tourists their bargaining chips. By Vivian Wang Reporting from Beijing China has ...

The therapy was engineered by researchers at Amgen. © 1996-2025 Amgen Inc. All Rights Reserved. Amgen’s global Phase III DeLLphi-304 trial of Imdelltra (tarlatamab ...